Results 51 to 60 of about 776,387 (309)

Non-small cell lung cancer [PDF]

Vnitřní lékařství, 2017
Non-small cell lung cancer (NSCLC) represents 80 % of diseases considering all patients with lung cancer. NSCLC comprises all histological types except for the small cell cancer. The treatment is chosen based on a clinical stage, morphological diagnosis and performance status of patients. In the low clinical stages a surgical solution is indicated.
Jana, Skřičková, Bohdan, Kadlec, Ondřej, Venclíček   +2 more
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer

, 2011
Chronic obstructive pulmonary disease (COPD) is a major burden throughout the world. It is associated with a significantly increased incidence of lung cancer and may influence treatment options and outcome.
Derek Grose MRCP, FRCR, Robert Milroy, Grose, Derek, Milroy, Robert   +3 more
core   +1 more source

MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer

Technology in Cancer Research & Treatment, 2020
MicroRNAs have been demonstrated to be critical regulators in tumor progression, including non-small cell lung cancer. MicroRNA-222-3p has been reported to function as a tumor suppressor or oncogene in several types of cancer, but its function role in ...
Weijun Chen MM, Xiaobo Li MM
doaj   +1 more source

Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations [PDF]

, 2012
KRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC), and tumors harboring these mutations tend to be aggressive and resistant to chemotherapy.
David Rossell, Xiaojia eTang, Tang, Xiaojia, Hossain, Asif, Rossell, David, Asha Nair, Jean-Pierre Kocher, Chai, High-Seng, Michael P. Walsh, Asif eHossain, Yan W. Asmann, Baker, Tiffany R., Edith A. Perez, Kalari, Krishna R., Necela, Brian M., Alan P. Fields, High Seng eChai, Xiaojia Tang, Alan P Fields, Leontovich, Alexey A., Carr, Jennifer, Thompson, E. Aubrey, Saurabh Baheti, Kocher, Jean-Pierre, Tiffany R Baker, Younkin, Curtis S., Walsh, Michael P., E. Aubrey Thompson, Jennifer M. Kachergus, Jennifer M Kachergus, Jennifer M Carr, Fields, Alan P., Asmann, Yan W., Krishna R. Kalari, E. Aubrey eThompson, Kachergus, Jennifer M., Steven N Hart, Krishna R Kalari, Jennifer M. Carr, David eRossell, Saurabh eBaheti, Steven N. Hart, Curtis S. Younkin, Zhifu eSun, Edith A Perez, Tiffany Baker, Brian M Necela, Alexey A. Leontovich, Nair, Asha, Perez, Edith A., Sun, Zhifu, Reisman, David N., Jean-Pierre eKocher, Asha eNair, Hart, Steven N., Yan W Asmann, Zhifu Sun, Michael eWalsh, Baheti, Saurabh, David N Reisman, Brian M. Necela, High-Seng Chai, David N. Reisman, Alexey A Leontovich, Asif Hossain, Curtis S Younkin   +65 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer

BMC Cancer
Objectives The 9th edition of the lung cancer tumor-node-metastasis (TNM) staging system downgrades certain non-small cell lung cancer (NSCLC) patients from stage IIIA (T1N2) to IIB(T1N2a).
Tong Wu, Jingsheng Cai, Yun Li, Rongjing Xie, Kezhong Chen   +4 more
doaj   +1 more source

HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer

Tumor Biology, 2017
Emerging evidence has demonstrated that the high expression of HBXIP has been correlated with many cancers. With evaluation of the functional role of HBXIP in non-small-cell lung cancer, the primary aim of this study is to investigate the correlation ...
Yixuan Wang, Nan Li, Shuanlong Che, Tiefeng Jin, Junjie Piao, Shuangping Liu, Zhenhua Lin   +6 more
doaj   +1 more source

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer [PDF]

, 2001
BACKGROUND: The incidence of lung cancer is declining following a drop in smoking rates, but it is still the leading cause of death from cancer in England and Wales, with about 30,000 deaths a year.
A. Clegg, N. Waugh, D. A. Scott, M. Sidhu, Waugh, N, Clegg, A. J., Scott, David A., Waugh, Norman, Clegg, A, Hewitson, P., Hewitson, P, Scott, D A, Sidhu, M, Sidhu, M. K., P. Hewitson   +14 more
core   +1 more source